AMT Starts Preregistration Trial for Glybera(TM)
Amsterdam (ots/PRNewswire) - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the treatment of the first patient in a preregistration clinical trial with Glybera(TM). This gene therapy product targets lipoprotein lipase deficiency (LPLD), a seriously debilitating and potentially lethal disease. The randomized controlled trial has been designed to ...